Please assess the completion status of the following clinical trial:

Trial Title: MK3207 for Treatment of Acute Migraines (3207-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women from 18 to 65 years of age~* 1+ year history of migraine that typically last from 4 to 72 hours if untreated~* Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months~* Not pregnant or planning to become pregnant in next 6 months~Exclusion Criteria:~* Pregnant or breast-feeding, or planning to become pregnant in next 6 months~* Cannot distinguish migraine attacks from tension type headaches~* Migraines are mild or resolve without medication in less than 2 hours~* More than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months~* Basilar type or hemiplegic migraine headaches~* More than 50 years old when migraines began~* History of cardiovascular disorder within last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK3207- 2.5 mg
- 2 (Type: EXPERIMENTAL): MK3207- 5 mg
- 3 (Type: EXPERIMENTAL): MK3207- 10 mg
- 4 (Type: EXPERIMENTAL): MK3207- 20 mg
- 5 (Type: EXPERIMENTAL): MK3207- 50 mg
- 6 (Type: EXPERIMENTAL): MK3207- 100 mg
- 7 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).